| Name | Title | Contact Details |
|---|
Cardeas BPU™ (Biosignal Processing Unit) is a biocompatible semiconductor capable of translating real-time streams of multiomics signals to digital information
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
L7 Informatics provides software and services that enable synchronized solutions for science + health. L7`s novel L7|ESP is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems to accelerate discoveries and drive precision healthcare.
Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health.
Pebble Labs Inc. is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security. Our mission is to develop breakthrough disruptive technologies that address the greatest agricultural, aquacultural, and environmental challenges facing the globe.